| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7413747 | UCB INC | Transdermal therapeutic system for treating Parkinsonism |
Mar, 2019
(5 years ago) | |
| US6699498 | UCB INC | Transdermal therapeutic systems having improved stability and their production |
Nov, 2020
(3 years ago) | |
| US6884434 | UCB INC | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar, 2021
(3 years ago) | |
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(8 months ago) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(1 year, 7 months from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(3 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(6 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(7 years from now) | |
Neupro is owned by Ucb Inc.
Neupro contains Rotigotine.
Neupro has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Neupro are:
- US7413747
- US6699498
- US6884434
- US8617591
Neupro was authorised for market use on 02 April, 2012.
Neupro is available in film, extended release;transdermal dosage forms.
Neupro can be used as treatment of restless legs syndrome by application of claimed transdermal delivery system, a method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
Drug patent challenges can be filed against Neupro from 10 May, 2011.
The generics of Neupro are possible to be released after 01 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-647) | Apr 02, 2015 |
| New Indication(I-646) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 02 April, 2012
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of r...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
